Skip to content
DataLookout
Menu

CHAMPNCT07572773

CHAMP Lung Cancer Screening Program

StatusSuspended
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Recruitment suspended Sponsor's reason: CVMC closed, will resume when replaced with another site that offers blood draw and CT capabilitie Show 4 more changesShow less
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised at 3 of 3 sites
    • Publications: details revised at 6 of 6 entries
  2. Notable Recruitment opened
    • Primary and study completion pushed from May 2028 to Jun 2028
    • Start date changed from estimate of Jun 1, 2026 to Jun 12, 2026
    • Site details revised at 3 of 3 sites
    v2
  3. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Proportion of pharmacy patrons receiving lung cancer screening
Timeframe: From enrollment through six months after enrollment

Secondary (4)

Proportion of eligible participants that receive a DELFI Diagnostics FirstLook lung cancer screening blood test
Determine the proportion of eligible participants that receive a low-dose CT scan
Correlations between demographic data and declining of initial screening
Frequency of individuals who complete screening in year 1 that return for screening in year 2

Arms and interventions

DELFI FirstLook Lung Cancer Screening Blood TestExperimental

Participants may choose to receive the DELFI Diagnostics FirstLook Lung test, a blood-based screening test designed to support early detection of lung cancer. The test analyzes patterns in cell-free DNA fragments using whole-genome sequencing and machine-learning techniques. Designed to augment traditional low-dose CT screening, it offers a minimally invasive and accessible option for early lung cancer detection. If a participant elects to receive this test, a blood sample will be collected at a study clinic and sent to a DELFI Diagnostics lab without any personal identifying health information attached. After processing, results are returned to the study team. Participants will be notified if results are not elevated, in which case repeating the test in one year is recommended. If results are elevated, study staff will recommend follow-up screening with a low-dose CT scan from local clinic for further evaluation. Both the blood test and CT will be provided by the study at no cost.

Low-Dose CTActive comparator

Participants can choose to follow current US Preventive Services Task Force recommendations of a low-dose CT scan ordered through their primary care physician.

No lung cancer screeningNo intervention

Participants chose to not participate in lung cancer screening. Annually, participants will be informed about lung cancer screening options and given the opportunity to participate in one of the screening options. Participants will have the ability to change their mind and choose one of the lung cancer screening options in between their annual screening discussion.

Diagnostic tests: DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test, Low-Does CT Scan

Sites

3 sites in 1 country